XML 105 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727
Stock-Based Compensation
12 Months Ended
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
Our shareholders previously approved the adoption of and subsequent amendments to the Lancaster Colony Corporation 2005 Stock Plan (the “2005 Plan”). The 2005 Plan reserved 2,000,000 common shares for issuance to our employees and directors, and all awards granted under the 2005 Plan will be exercisable at prices not less than fair market value as of the date of the grant. The vesting period for awards granted under the 2005 Plan varies as to the type of award granted, but generally these awards have a maximum term of five years. We intend to solicit shareholder approval for adoption of a new equity compensation plan at our November 2015 Annual Meeting of Shareholders, as the 2005 Plan expired in May 2015.
Stock-Settled Stock Appreciation Rights
We use periodic grants of stock-settled stock appreciation rights (“SSSARs”) as a vehicle for rewarding certain employees with long-term incentives for their efforts in helping to create long-term shareholder value. We calculate the fair value of SSSARs grants using the Black-Scholes option-pricing model. Our policy is to issue shares upon SSSARs exercise from new shares that had been previously authorized.
In 2015, 2014 and 2013, we granted SSSARs to various employees under the terms of the 2005 Plan. The following table summarizes information relating to these grants:
 
2015
 
2014
 
2013
SSSARs granted
149

 
146

 
108

Weighted average grant date fair value per right
$
9.94

 
$
11.84

 
$
9.04

Weighted average assumptions used in fair value calculations:
 
 
 
 
 
Risk-free interest rate
0.86
%
 
0.75
%
 
0.33
%
Dividend yield
2.02
%
 
1.97
%
 
2.09
%
Volatility factor of the expected market price of our common stock
19.62
%
 
22.35
%
 
23.23
%
Weighted average expected life in years
2.71

 
3.12

 
2.67


For these grants, the volatility factor was estimated based on actual historical volatility of our stock for a time period equal to the term of the SSSARs. The expected average life was determined based on historical exercise experience for this type of grant. The SSSARs we grant vest one-third on the first anniversary of the grant date, one-third on the second anniversary of the grant date and one-third on the third anniversary of the grant date. As needed, we estimate a forfeiture rate for our SSSARs grants based on historical experience.
We recognize compensation expense over the requisite service period. Compensation expense was reflected in Cost of Sales or Selling, General and Administrative Expenses based on the grantees’ salaries expense classification. We recorded tax benefits and excess tax benefits related to SSSARs. These excess tax benefits were included in the financing section of the Consolidated Statements of Cash Flows. The following table summarizes our continuing operations SSSARs compensation expense and tax benefits recorded for each of the years ended June 30:
 
2015
 
2014
 
2013
Compensation expense
$
1,288

 
$
1,092

 
$
1,316

Tax benefits
$
451

 
$
382

 
$
461

Intrinsic value of exercises
$
1,162

 
$
2,692

 
$
1,851

Excess tax benefits
$
410

 
$
942

 
$
659


The total fair values of SSSARs vested for each of the years ended June 30 were as follows:
 
2015
 
2014
 
2013
Fair value of vested rights
$
1,252

 
$
1,145

 
$
1,476


 The following table summarizes the activity relating to SSSARs granted under the 2005 Plan for the year ended June 30, 2015:
 
Number of
Rights
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Life in
Years
 
Aggregate
Intrinsic
Value
Outstanding at beginning of year
358

 
$
76.75

 
 
 
 
Exercised
(81
)
 
$
65.77

 
 
 
 
Granted
149

 
$
91.13

 
 
 
 
Forfeited
(31
)
 
$
79.42

 
 
 
 
Outstanding at end of year
395

 
$
84.24

 
3.58
 
$
2,653

Exercisable and vested at end of year
128

 
$
75.55

 
2.48
 
$
1,956

Vested and expected to vest at end of year
386

 
$
84.26

 
3.58
 
$
2,581


The following table summarizes information about the SSSARs outstanding by grant year at June 30, 2015:
 
 
Outstanding
 
Exercisable
 
 
 
 
 
 
Weighted Average
 
 
 
 
Grant Years
 
Range of
Exercise Prices
 
Number
Outstanding
 
Remaining
Contractual
Life in
Years
 
Exercise
Price
 
Number
Exercisable
 
Weighted
Average
Exercise
Price
2015
 
$91.13
 
149
 
4.66
 
$91.13
 
 
$—
2014
 
$79.78-$89.29
 
131
 
3.65
 
$89.14
 
43
 
$89.14
2013
 
$72.67
 
56
 
2.66
 
$72.67
 
26
 
$72.67
2012
 
$63.50-$68.12
 
52
 
1.65
 
$68.05
 
52
 
$68.05
2011
 
$57.78
 
7
 
0.65
 
$57.78
 
7
 
$57.78

At June 30, 2015, there was $1.9 million of unrecognized compensation expense related to SSSARs that we will recognize over a weighted-average period of 2 years.
Restricted Stock
We use periodic grants of restricted stock as a vehicle for rewarding our nonemployee directors and certain employees with long-term incentives for their efforts in helping to create long-term shareholder value.
In 2015, 2014 and 2013, we granted shares of restricted stock to various employees under the terms of the 2005 Plan. The following table summarizes information relating to these grants:
 
2015
 
2014
 
2013
Employees
 
 
 
 
 
Restricted stock granted
9

 
24

 
8

Grant date fair value
$
845

 
$
2,190

 
$
572

Weighted average grant date fair value per award
$
91.13

 
$
89.21

 
$
72.67


The restricted stock under these employee grants vests on the third anniversary of the grant date. As needed, we estimate a forfeiture rate for our restricted stock grants based on historical experience. Under the terms of our grants, employees receive dividends on unforfeited restricted stock regardless of their vesting status. In 2015, 2014 and 2013, 20,000, 6,000 and 23,000 shares, respectively, of employee restricted stock vested.
In 2015, 2014 and 2013, we also granted shares of restricted stock to our nonemployee directors under the terms of the 2005 Plan. The following table summarizes information relating to each of these grants:
 
2015
 
2014
 
2013
Nonemployee directors
 
 
 
 
 
Restricted stock granted
7

 
6

 
7

Grant date fair value
$
639

 
$
490

 
$
490

Weighted average grant date fair value per award
$
92.92

 
$
84.42

 
$
73.29


The 2015 grant vests over a one-year period, and all of these shares are expected to vest. Dividends earned on the stock during the vesting period will be paid to the directors at the time the stock vests. In 2015, 2014 and 2013, 6,000, 7,000 and 7,000 shares, respectively, of nonemployee director restricted stock vested, and the directors were paid the related dividends.
We recognize compensation expense over the requisite service period. Compensation expense was reflected in Cost of Sales or Selling, General and Administrative Expenses based on the grantees’ salaries expense classification. We recorded tax benefits and excess tax benefits related to restricted stock. These excess tax benefits were included in the financing section of the Consolidated Statements of Cash Flows. The following table summarizes our continuing operations restricted stock compensation expense and tax benefits recorded for each of the years ended June 30:
 
2015
 
2014
 
2013
Compensation expense
$
1,752

 
$
1,434

 
$
1,411

Tax benefits
$
613

 
$
502

 
$
494

Excess tax benefits
$
153

 
$
78

 
$
135


The total fair values of restricted stock vested for each of the years ended June 30 were as follows:
 
2015
 
2014
 
2013
Fair value of vested shares
$
1,836

 
$
931

 
$
1,842


The following table summarizes the activity relating to restricted stock granted under the 2005 Plan for the year ended June 30, 2015:
 
Number of
Shares
 
Weighted
Average Grant
Date Fair Value
Unvested restricted stock at beginning of year
58

 
$
79.09

Granted
16

 
$
91.89

Vested
(26
)
 
$
71.84

Forfeited
(3
)
 
$
79.64

Unvested restricted stock at end of year
45

 
$
87.71


At June 30, 2015, there was $2.2 million of unrecognized compensation expense related to restricted stock that we will recognize over a weighted-average period of 2 years.